Ruxolitinib in COVID-19 patients with defined hyperinflammation: the RuxCoFlam trial

被引：0

作者：

Birndt, S. ^{[1
]}

Hammersen, J. ^{[1
]}

Doehner, K. ^{[2
]}

Reuken, P. ^{[3
]}

Sauerbrey, P. ^{[1
]}

La Rosee, F. ^{[4
]}

Pfirrmann, M. ^{[5
]}

Fabisch, C. ^{[1
]}

Weiss, M. ^{[6
]}

Traeger, K. ^{[6
]}

Bremer, H. ^{[7
]}

Illerhaus, G. ^{[8
]}

Droemann, D. ^{[9
]}

Schneider, S. ^{[10
]}

La Rosee, P. ^{[11
]}

Hochhaus, A. ^{[1
]}

机构：

[1] Univ Klinikum Jena, Klin Innere Med Hamatol & Internist Onkol 2, Jena, Germany

[2] Univ Klinikum Ulm, Klin Innere Med 3, Ulm, Germany

[3] Univ Klinikum Jena, Klin Innere Med 4, Interdisziplinare Endoskopie, Hepatol,Infektiol,Gastroenterol, Jena, Germany

[4] Univ Klinikum Dresden, Med Fak, Dresden, Germany

[5] LMU Munchen, Inst Med Informat Verarbeitung Biometrie & Epidem, Med Fak, Munich, Germany

[6] Univ Klinikum Ulm, Klin Anasthesiol & Intens Med, Ulm, Germany

[7] Schwarzwald Baar Klinikum, Lungenzentrum Donaueschingen, Donaueschingen, Germany

[8] Klinikum Stuttgart, Klin Hamatol Onkol Stammzellentransplantat & Pall, Stuttgart, Germany

[9] Univ Klinikum Schleswig Holstein, Med Klin Pulmol 3, Campus Lubeck, Lubeck, Germany

[10] SRH Klinikum Gera, Gera, Germany

[11] Schwarzwald Baar Klinikum, Klin Innere Med Hamatol Onkol Immunol Infektiol &, Villingen Schwenningen, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V497

引用

页码：71 / 71

页数：1

共 50 条

[41] Systemic hyperinflammation as a driver of maculopapular drug exanthema in severely ill COVID-19 patients?
Mitamura, Y.
Schulz, D.
Kolm, I.
Oro, S.
Levesque, M.
Maverakis, E.
Akdis, C.
Bruggen, M.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (05) : S2 - S2
[42] COVID-19: lambda interferon against viral load and hyperinflammation
Andreakos, Evangelos
Tsiodras, Sotirios
EMBO MOLECULAR MEDICINE, 2020, 12 (06)
[43] Management of severe hyperinflammation in the COVID-19 era: the role of the rheumatologist
Papadopoulou, Charalampia
Al Obaidi, Muthana
Moraitis, Elena
Compeyrot-Lacassagne, Sandrine
Eleftheriou, Despina
Brogan, Paul
RHEUMATOLOGY, 2021, 60 (02) : 911 - 917
[44] ACEi reduces hypertension-induced hyperinflammation in COVID-19
Lim, Gregory B.
NATURE REVIEWS CARDIOLOGY, 2021, 18 (04) : 231 - 231
[45] Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?
Ritchie, Andrew I.
Singanayagam, Aran
LANCET, 2020, 395 (10230) : 1111 - 1111
[46] Inhibition of MPC Simultaneously Mitigates Hyperinflammation and Hyperglycemia in COVID-19
Sun, J.
Zhu, B.
Wei, X.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
[47] A brewing storm: The neuropsychological sequelae of hyperinflammation due to COVID-19
Cothran, Thomas P.
Kellman, Suzanne
Singh, Shifali
Beck, Jonathan S.
Powell, Karina J.
Bolton, Corey J.
Tam, Joyce W.
BRAIN BEHAVIOR AND IMMUNITY, 2020, 88 : 957 - 958
[48] Outcomes of COVID-19 Infection in Patients Receiving Ruxolitinib and Hypomethylating Agent Therapy
Nathan, Daniel I.
Tremblay, Douglas
Thibaud, Santiago
Mascarenhas, John
Gabrilove, Janice L.
BLOOD, 2020, 136
[49] A Randomized Double-Blinded Placebo Controlled Trial of Clazakizumab for the Treatment of COVID-19 Pneumonia With Hyperinflammation*
Lonze, Bonnie E.
Spiegler, Peter
Wesson, Russell N.
Alachkar, Nada
Petkova, Eva
Weldon, Elaina P.
Dieter, Rebecca A.
Li, Yi
Quinn, Max
Mattoo, Aprajita
Soomro, Irfana
Cohen, Steven M.
Leung, Sherry
Deterville, Cecilia L.
Landrum, B. Mark
Ali, Muhammad Imran
Cohen, David J.
Singer, Andrew L.
Sen, Ayan
Chong, Edward
Hochman, Judith S.
Troxel, Andrea B.
Montgomery, Robert A.
CRITICAL CARE MEDICINE, 2022, 50 (09) : 1348 - 1359
[50] Hyperinflammation and Fibrosis in Severe COVID-19 Patients: Galectin-3, a Target Molecule to Consider
Garcia-Revilla, Juan
Deierborg, Tomas
Venero, Jose Luis
Boza-Serrano, Antonio
FRONTIERS IN IMMUNOLOGY, 2020, 11

← 1 2 3 4 5 →